Brief: Ikena Oncology Shares Initial Positive Dose Escalation Data From IK-930 Phase I Trial And Reports Third Quarter 2023 Results
09/11/2023 12:35
Nov 9 (Reuters) - Ikena Oncology Inc IKNA.O :
* IKENA ONCOLOGY SHARES INITIAL POSITIVE AND DIFFERENTIATED
DOSE
ESCALATION DATA FROM IK-930 PHASE I TRIAL AND REPORTS THIRD
QUARTER 2023 FINANCIAL RESULTS
* IKENA ONCOLOGY INC: ADDITIONAL IK-930 CLINICAL DATA UPDATE
PLANNED FOR SECOND HALF OF 2024
* IKENA ONCOLOGY INC: FAVORABLE SAFETY PROFILE IN DOSE
ESCALATION
SHOWN TO DATE FROM TRIAL
Source text for Eikon: ID:nGNX5Llt48
Further company coverage: IKNA.O
((Reuters.Briefs@thomsonreuters.com;))
Recent news on ImageneBio
See all newsImageneBio Inc reports results for the quarter ended June 30 - Earnings Summary
Brief: ImageneBio - Appoints Yanina Grant-Huerta As Chief Financial Officer Effective July 20, 2026 - SEC Filing
ImageneBio Inc expected to post a loss of 89 cents a share - Earnings Preview
U.S. STOCKS ON THE MOVE-Conagra, Oracle, Replimune
U.S. STOCKS ON THE MOVE-Allogene Therapeutics, Adobe, Williams-Sonoma